Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MBT Companion Study for Pegbelfermin in NASH
NCT03611101Phase 2Completed
- Sponsor
- Meridian Bioscience
- Start
- May 2018
- Primary completion
- Aug 2020
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of pegbelfermin in Nonalcoholic steatohepatitis (NASH), Liver Fibrosis (LF) and Liver cirrhosis (LC) (4 arms), sponsored by Meridian Bioscience. Primary endpoint: Percent Change in ¹³C-Methacetin Breath Test at 48 weeks. Started May 2018; status: completed.
02
Drugs
pegbelfermin
03
Conditions
Nonalcoholic steatohepatitis (NASH)Liver Fibrosis (LF)Liver cirrhosis (LC)
Beyond the preview
Go deeper on NCT03611101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03611101.